14
nanotimes
Companies Facts
4,070,681 no par value common shares in bearer form with an imputed nominal value of EUR1.00 by EUR56,360.00 to EUR4,127,041.00. Dr. Peter Heinrich, CEO of MagForce AG, along with interna- tional investors participated in the share placement. The company excluded subscription rights to existing shareholders by its authority. A total of 56,360.00 new common bearer shares with profit participation rights dating from January 1, 2011 were issued in the private placement at a price of EUR12.42 per
share. The gross proceeds of the capital increase in the amount of approx. EUR700,000.00 will go to the company and will be used to finance its further growth.
Moreover, the Company announced the treatment of a recurrent glioblastoma patient with the company‘s NanoTherm®
therapy. The first part of the therapy
(instillation of the nanoparticles) was carried out at the University Giessen and subsequent steps (nano-
11-09 :: September 2011
Advertisement
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67